Tweenvest Stocks

Astria Therapeutics, Inc. (NasdaqGM: ATXS)

Health Care · Biotechnology · US

$

0.00% today · 1Y

Astria Therapeutics, Inc. (NasdaqGM: ATXS) operates in the Biotechnology industry within the Health Care sector.

trading between 6.09 and 13.29.

Tweenvest scores Astria Therapeutics, Inc. across four factors: quality 30/100, value 55/100. Its strongest factor is value.

ATXS price history

Not enough price history to draw a chart yet.

Key figures

Market cap
Revenue (TTM)
$706.00K
P/E
EPS
-2.14
Dividend yield
Beta (5Y)
52-week high
$13.29
52-week low
$6.09
Avg volume (3M)
Shares outstanding
Employees
78
Next earnings

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.

ISIN
US04635X1028
Founded
2008
Listed since
Jun 25, 2015
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$464.58B$262.90-1.09%
Amgen Inc.NasdaqGS: AMGN$238.06B$440.34-0.43%
Gilead Sciences, Inc.NasdaqGS: GILD$183.64B$148.10-0.45%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.72B$547.29-1.01%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$81.36B$814.79-2.25%
argenx SEENXTBR: ARGX$64.17B897.60+2.09%
Moderna, Inc.NasdaqGS: MRNA$63.41B$149.66-5.77%
CSL LimitedASX: CSL$59.19BAU$172.44-0.69%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.